tiprankstipranks
Trending News
More News >

BioXcel Therapeutics target adjusted to $8 from $3 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on BioXcel Therapeutics (BTAI) to $8 from $3 and keeps a Buy rating on the shares. The firm cites After the dilution associated with the most recent equity financing in March as well as the impact of the reverse stock split implemented in February for the new target.

Don’t Miss TipRanks’ Half-Year Sale

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1